Results 121 to 130 of about 1,326 (158)

The impact of adding optical coherence tomography in MS diagnostic criteria on the classification of tumefactive demyelination. [PDF]

open access: yesJ Neurol Sci
Guido FS   +13 more
europepmc   +1 more source

Cyclophosphamide in treatment of tumefactive multiple sclerosis

Multiple Sclerosis and Related Disorders, 2021
. To review the Mayo clinic experience of cyclophosphamide in the treatment of tumefactive Multiple Sclerosis (TMS).. Retrospective chart review was performed to identify patients with TMS who did not respond to corticosteroid and plasma exchange and were treated with cyclophosphamide.
W Oliver Tobin
exaly   +3 more sources

Late-onset tumefactive multiple sclerosis

Radiation Medicine, 2008
A patient with tumefactive multiple sclerosis (MS) initially presented at the age of 87 years; the revised diagnostic criteria from the International Panel on MS (2001) were fulfilled. Late-onset MS and tumefactive demyelinating lesions are discussed. This case suggests that MS can occur at any age. MS should be borne in mind for differential diagnosis
Motoki Nakai   +2 more
exaly   +3 more sources

Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders

Current Neurology and Neuroscience Reports, 2016
Tumefactive demyelinating lesions are rare consequences of central nervous system (CNS) idiopathic inflammatory demyelinating diseases. Tumefactive demyelinating lesions pose a diagnostic challenge because they can mimic tumors and abscesses and because they can be caused by a heterogeneous range of disorders. This article reviews the recent literature
Michelle Cameron
exaly   +3 more sources

Focal Hyperhidrosis in Tumefactive Multiple Sclerosis

Archives of Neurology, 2010
No abstract ...
Iorio, Raffaele   +7 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy